Repligen says BioLife deal targets Q4 close pending regulatory, shareholder approvals

Reuters2026/08/03 21:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Repligen agreed to acquire BioLife Solutions, expanding its footprint in cell therapy tools and biopreservation media.
The deal was announced July 22.
Closing is expected in the fourth quarter, subject to regulatory and shareholder approvals.
Until closing, the two companies will continue to operate as separate, independent businesses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLife Solutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-051964), on August 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Repligen says BioLife deal targets Q4 close pending regulatory, shareholder approvals

You may also like

Crypto prices